Assessing AtaiBeckley (ATAI) Valuation After Trial Success Index Addition Capital Raise And US Move

AtaiBeckley (ATAI) has drawn fresh attention after positive late stage BPL-003 data in treatment resistant depression, inclusion in the NASDAQ Biotechnology Index, a US$300 million capital raise, and its move to a U.S. corporate base. See our latest analysis for AtaiBeckley. AtaiBeckley’s recent clinical updates, index inclusion, and capital raise sit against a mixed share price backdrop, with a 1 day share price return of 5.8% contrasting with a 90 day share price return decline of 30.6%,...